UniQure EBITDA Margin 2013-2022 | QURE
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for UniQure (QURE) over the last 10 years. The current EBITDA margin for UniQure as of December 31, 2022 is .
| UniQure EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2022-09-30 |
$0.06B |
$-0.16B |
-260.66% |
| 2022-06-30 |
$0.06B |
$-0.15B |
-233.87% |
| 2022-03-31 |
$0.53B |
$0.31B |
58.75% |
| 2021-12-31 |
$0.52B |
$0.32B |
60.69% |
| 2021-09-30 |
$0.50B |
$0.31B |
61.60% |
| 2021-06-30 |
$0.50B |
$0.31B |
62.20% |
| 2021-03-31 |
$0.04B |
$-0.13B |
-328.95% |
| 2020-12-31 |
$0.04B |
$-0.12B |
-302.63% |
| 2020-09-30 |
$0.01B |
$-0.14B |
-2000.00% |
| 2020-06-30 |
$0.01B |
$-0.13B |
-2166.67% |
| 2020-03-31 |
$0.01B |
$-0.12B |
-2033.33% |
| 2019-12-31 |
$0.01B |
$-0.12B |
-1642.86% |
| 2019-09-30 |
$0.01B |
$-0.11B |
-1766.67% |
| 2019-06-30 |
$0.01B |
$-0.09B |
-1150.00% |
| 2019-03-31 |
$0.01B |
$-0.08B |
-933.33% |
| 2018-12-31 |
$0.01B |
$-0.08B |
-690.91% |
| 2018-09-30 |
$0.01B |
$-0.08B |
-625.00% |
| 2018-06-30 |
$0.01B |
$-0.07B |
-600.00% |
| 2018-03-31 |
$0.01B |
$-0.06B |
-484.62% |
| 2017-12-31 |
$0.01B |
$-0.06B |
-484.62% |
| 2017-09-30 |
$0.02B |
$-0.06B |
-300.00% |
| 2017-06-30 |
$0.02B |
$-0.06B |
-262.50% |
| 2017-03-31 |
$0.02B |
$-0.07B |
-291.30% |
| 2016-12-31 |
$0.02B |
$-0.07B |
-279.17% |
| 2016-09-30 |
$0.02B |
$-0.06B |
-289.47% |
| 2016-06-30 |
$0.02B |
$-0.07B |
-443.75% |
| 2016-03-31 |
$0.01B |
$-0.07B |
-500.00% |
| 2015-12-31 |
$0.01B |
$-0.07B |
-600.00% |
| 2015-09-30 |
$0.01B |
$-0.08B |
-877.78% |
| 2015-06-30 |
$0.01B |
$-0.07B |
-1083.33% |
| 2015-03-31 |
$0.01B |
$-0.06B |
-1160.00% |
| 2014-12-31 |
$0.01B |
$-0.05B |
-900.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.946B |
$0.106B |
|
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
|
